Anti-CTAg Antibodies Identified in Stage I, II Melanoma
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Oct. 2, 2024 -- Circulating antibodies against cancer-testis antigens (CTAgs) are found in stage I and stage II melanoma plasma samples, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25 to 28 in Amsterdam.
Cristina Vico-Alonso, M.D., from Monash University Public Health and Preventive Medicine in Melbourne, Australia, and colleagues examined whether anti-CTAg antibodies can aid in the early detection of melanoma using plasma samples from two cohorts. Cohort 1 included 264 patients diagnosed with melanoma in situ, stage I and stage II; cohort 2 included 108 heathy individuals without melanoma. Two different CTAg microarray platforms were used to profile the antibodies present in plasma (CT100+ and the Sengenics CTA Protein Microarrays).
To date, the CT100+ array has been used to assay 199 plasma samples from patients in cohort 1. The antibody profile was compared to results from 38 healthy individuals from cohort 2. The researchers identified specific immunoglobulin G antibodies against three tumor antigens as promising diagnostic biomarkers for early-stage melanomas; in the discovery and internal validation cohorts, the univariate areas under the curve varied from 0.857 to 0.981 and from 0.824 to 0.985, respectively.
"This method of early detection could be integrated into current melanoma screening practices to provide additional information, especially in uncertain cases, potentially avoiding unnecessary procedures," Vico-Alonso said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
32 Percent of U.S. Adults Consumed Fast Food on a Given Day in 2021 to 2023
FRIDAY, June 27, 2025 -- Over 30 percent of adults and children consumed fast food on a given day during August 2021 to August 2023, according to two reports from the National...
Disparities Seen in Continuous Glucose Monitor Rx by Language Preference
FRIDAY, June 27, 2025 -- For patients with type 2 diabetes (T2D), disparities in continuous glucose monitor (CGM) prescriptions are seen by language preference, with less access...
Survey Shows Few Adults Recognize Testicular Cancer as Affecting Young Men
FRIDAY, June 27, 2025 -- Only one in 10 U.S. adults correctly identified testicular cancer as most commonly affecting men under age 40, according to a survey released June16 by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.